Total Payments
$25,713
2024 Payments
$7,785
Companies
79
Transactions
964
Medicare Patients
13,015
Medicare Billing
$4.8M
Payment Breakdown by Category
Food & Beverage$16,130 (62.7%)
Consulting$6,609 (25.7%)
Travel$2,399 (9.3%)
Other$258.60 (1.0%)
Research$181.98 (0.7%)
Education$134.35 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $16,130 | 921 | 62.7% |
| Consulting Fee | $6,609 | 5 | 25.7% |
| Travel and Lodging | $2,399 | 14 | 9.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $258.60 | 15 | 1.0% |
| Unspecified | $181.98 | 2 | 0.7% |
| Education | $134.35 | 7 | 0.5% |
Payments by Type
General
$25,531
962 transactions
Research
$181.98
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $5,996 | 26 | $0 (2024) |
| Merck Sharp & Dohme LLC | $2,102 | 78 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,641 | 119 | $0 (2024) |
| EMD Serono, Inc. | $1,555 | 4 | $0 (2024) |
| Janssen Biotech, Inc. | $1,262 | 69 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $982.66 | 59 | $0 (2023) |
| PFIZER INC. | $860.91 | 62 | $0 (2024) |
| Amgen Inc. | $852.94 | 57 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $843.86 | 52 | $0 (2024) |
| Genentech USA, Inc. | $838.68 | 74 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,785 | 100 | ABBVIE INC. ($5,760) |
| 2023 | $4,185 | 134 | EMD Serono, Inc. ($1,500) |
| 2022 | $2,807 | 144 | Novartis Pharmaceuticals Corporation ($348.97) |
| 2021 | $1,371 | 88 | Pharmacyclics LLC, An AbbVie Company ($188.73) |
| 2020 | $948.06 | 42 | Foundation Medicine, Inc. ($180.03) |
| 2019 | $3,741 | 146 | Merck Sharp & Dohme Corporation ($1,171) |
| 2018 | $1,968 | 147 | Amgen Inc. ($273.19) |
| 2017 | $2,908 | 163 | Intuitive Surgical, Inc. ($773.45) |
All Payment Transactions
964 individual payment records from CMS Open Payments — Page 1 of 39
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: Oncology | ||||||
| 11/06/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $725.00 | General |
| 10/25/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $20.92 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $36.83 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,334.00 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $246.56 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $18.00 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $12.28 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $104.30 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $11.79 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: ONCOLOGY | ||||||
| 08/12/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $245.22 | General |
| 07/26/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $18.00 | General |
| 07/23/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,900.00 | General |
| 07/16/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $21.84 | General |
| Category: Oncology | ||||||
| 07/03/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $21.56 | General |
| Category: ONCOLOGY | ||||||
| 06/29/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: ONCOLOGY | ||||||
| 06/29/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 06/27/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $23.35 | General |
| 06/26/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: Oncology | ||||||
| 06/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: ONCOLOGY | ||||||
| 06/19/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: ONCOLOGY | ||||||
| 06/19/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $14.40 | General |
| Category: HORMONE THERAPY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment | SANOFI-AVENTIS U.S. LLC | $155.58 | 1 |
| RANDOMIZED STUDY OF AM0010 IN COMBINATION WITH FOLFOX COMPARED TO FOLFOX ALONE AS SECOND-LINE TX IN PTS WITH META PANCREATIC CANCER THAT HAS PROGRESSED DURING OR FOLLOWING A FIRST-LINE GEMCITABINE CONTAINING REGIMEN | Eli Lilly and Company | $26.40 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 74 | 3,770 | 126,715 | $9.2M | $2.6M |
| 2022 | 73 | 3,381 | 56,179 | $4.8M | $1.2M |
| 2021 | 57 | 2,683 | 22,655 | $1.8M | $444,418 |
| 2020 | 66 | 3,181 | 47,391 | $2.1M | $510,161 |
Total Patients
13,015
Total Services
252,940
Medicare Billing
$4.8M
Procedure Codes
270
All Medicare Procedures & Services
270 procedure records from CMS Medicare Utilization — Page 1 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 23 | 26,300 | $3.4M | $1.1M | 32.8% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 12 | 37,300 | $2.7M | $881,307 | 32.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 373 | 1,638 | $327,600 | $148,196 | 45.2% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 65 | 84 | $504,000 | $89,460 | 17.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 77 | 612 | $308,448 | $58,316 | 18.9% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 63 | 81 | $63,180 | $33,177 | 52.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 123 | 249 | $74,700 | $33,037 | 44.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 72 | 1,560 | $117,000 | $17,883 | 15.3% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 11 | 83 | $42,698 | $16,348 | 38.3% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 23 | 11,830 | $91,719 | $16,238 | 17.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 12 | 111 | $313,424 | $15,002 | 4.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 80 | 80 | $36,000 | $12,630 | 35.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 46 | 263 | $63,646 | $12,468 | 19.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 225 | 1,076 | $78,548 | $11,137 | 14.2% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 40 | 59 | $89,503 | $9,695 | 10.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 263 | 1,080 | $25,920 | $9,072 | 35.0% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 15 | 502 | $74,798 | $8,609 | 11.5% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2023 | 212 | 1,019 | $43,817 | $6,460 | 14.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 37 | 127 | $27,178 | $5,842 | 21.5% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 65 | 96 | $97,824 | $5,252 | 5.4% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 48 | 74 | $91,834 | $5,239 | 5.7% |
| 85007 | Microscopic examination for white blood cells with manual cell count | Office | 2023 | 212 | 1,019 | $27,513 | $3,791 | 13.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 29 | 177 | $20,355 | $3,716 | 18.3% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 80 | 200 | $23,800 | $3,292 | 13.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 26 | 149 | $20,860 | $3,186 | 15.3% |
About Dr. James Wade, M.D
Dr. James Wade, M.D is a Medical Oncology healthcare provider based in Decatur, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992774459.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Wade, M.D has received a total of $25,713 in payments from pharmaceutical and medical device companies, with $7,785 received in 2024. These payments were reported across 964 transactions from 79 companies. The most common payment nature is "Food and Beverage" ($16,130).
As a Medicare-enrolled provider, Wade has provided services to 13,015 Medicare beneficiaries, totaling 252,940 services with total Medicare billing of $4.8M. Data is available for 4 years (2020–2023), covering 270 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Decatur, IL
- Active Since 03/16/2006
- Last Updated 02/26/2014
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1992774459
Products in Payments
- VENCLEXTA (Drug) $1,961
- KEYTRUDA (Biological) $1,944
- IMBRUVICA (Drug) $1,065
- Da Vinci Surgical System (Device) $773.45
- Lenvima (Drug) $376.60
- FOUNDATIONONE (Device) $365.77
- KISQALI (Drug) $353.94
- PROMACTA (Drug) $353.41
- DARZALEX (Biological) $329.78
- Neulasta (Biological) $307.38
- JEVTANA (Drug) $303.35
- VERZENIO (Drug) $299.97
- Imbruvica (Drug) $283.99
- LYNPARZA (Drug) $275.75
- IMLYGIC (Biological) $258.60
- ERLEADA (Drug) $230.43
- FOUNDATIONONE CDX (Device) $229.00
- XTANDI (Drug) $228.97
- Rubraca (Drug) $218.58
- IMFINZI (Biological) $213.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Decatur
Dr. Hagop Youssoufian, M.d, M.D
Medical Oncology — Payments: $78,000
Medical Oncology $78,000
Mr. Mario Velasco, Md, MD
Medical Oncology — Payments: $19,437
Medical Oncology $19,437
Dr. Naveen Lobo, Md, MD
Medical Oncology — Payments: $8,631
Medical Oncology $8,631
Dr. Zeba Aziz, M.d, M.D
Medical Oncology
Medical Oncology
Dr. Emiliana Sandiego, M.d, M.D
Medical Oncology
Medical Oncology
Dr. Haig Yardumian, D. O, D. O
Medical Oncology
Medical Oncology